GSK shares results from phase 3 trial for gonorrhoea treatment
April 18, 2024Research and Development GSK, Reproductive health, clinical trial, gonorrhoea, sexual health
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential first-in-class oral antibiotic for the …
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
April 18, 2024Research and Development Ear Nose & throat, Eli Lilly, clinical trial, sleep apnoea, tirzepatide
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated that tizepatide injection (10mg or …
Medincell and AbbVie enter agreement for development of next-generation injectables
April 17, 2024Research and Development AbbVie, Immunology, Medincell, collaboration
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and commercialise up to six next-generation …
Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy
April 17, 2024Research and Development Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …
Novartis shares new data about Fabhalta for IgAN treatment
April 16, 2024Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …
GSK’s meningococcal vaccine candidate accepted for FDA review
April 16, 2024Medical Communications FDA, GSK, Immunology, meningococcal
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
April 15, 2024Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
April 15, 2024Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …
Lipocine announces results from phase 2 trial for obesity drug
April 12, 2024Research and Development Lipocine, Obesity, clinical trial, weight loss
Lipocine Inc has announced results from its phase 2 clinical trial (NCT04134091), which includes results for LPCN 2401, the company’s …
Baxter expands US portfolio with new injectables
April 12, 2024Medical Communications Pharmacy, baxter, injectables, product launch
Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of five new injectable products in …
Vertex to acquire Alpine Immune Sciences for $4.9bn
April 11, 2024Business Services Alpine Immune Sciences, Nephrology, Vertex pharmaceuticals, acquisition, nephropathy
Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will …
NICE recommends migraine treatment for NHS use
April 11, 2024Medical Communications NHS, NICE, Neurology, migraine
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …
TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
April 10, 2024Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
April 10, 2024Research and Development FDA, Oncology, Oryzon, lung cancer
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …
An overview of women’s health in 2024
April 9, 2024Reproductive health, abortion, fertility, reproductive health, women's health
Betsy Goodfellow from Pharmafocus considers the current landscape of women’s health, covering recent debates and ongoing issues within the reproductive health sphere …
Gilead’s Veklury recommended by NICE for COVID-19 treatment
April 9, 2024Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …
PureTech Health launches Seaport Therapeutics
April 9, 2024Business Services Financing, Neurology, PureTech Health, launch
PureTech Health has announced key progress on its ‘strategic initiatives to deliver innovative medicines to patients and unlock value for …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
April 8, 2024Research and Development Cancer, Geneos Therapeutics, Oncology, clinical trial
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from the full cohort of patients …
Johnson & Johnson to acquire Shockwave Medical
April 8, 2024Business Services Cardiology, Johnson & Johnson, Shockwave Medical, acquisition
Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J …
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
April 5, 2024Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
